U CAN-CER VIVE Supports Karmanos Cancer Institute
U CAN-CER VIVE has recently made a significant contribution of $459,010 to the Karmanos Cancer Institute, aimed at advancing innovative cancer treatment research utilizing radiofrequency electromagnetic fields. This funding will enable Karmanos researchers to explore new clinical trials aimed at treating various types of cancer, including breast, colorectal, and pancreatic cancers. Notably, it will build upon investigations into liver cancer treatments using the novel TheraBionic P1 device.
Investing in Innovative Cancer Treatment
The generous grant from U CAN-CER VIVE Foundation was presented to the Karmanos team in the spring, reaffirming the foundation’s commitment to impactful cancer research. Co-founded by Ryan and Kelley LaFontaine, the U CAN-CER VIVE Foundation is known for supporting vital cancer research initiatives across the region. The funds secured will open pathways for clinical trials and further the study of revolutionary treatments, thus expanding research horizons within the medical community.
Purpose-Built Devices for Cancer Therapy
The TheraBionic P1 device represents a significant advancement in cancer therapy. Recently FDA-approved, it is designed uniquely to treat advanced liver cancer, specifically hepatocellular carcinoma. With over two decades of research backing its effectiveness, this device has shown promising results in reducing tumor sizes and improving survival rates without major side effects like those associated with conventional therapies.
Clinical Advancements and Patient Care
Through continued research and application of the TheraBionic P1, Karmanos can harness cutting-edge technology that enables personalized treatment plans for patients. Anthony Shields, M.D., Ph.D., an essential figure in clinical oncology at Karmanos, emphasizes that the device provides clear benefits, showcasing its effectiveness among patients with advanced liver cancer.
Future of Cancer Research with U CAN-CER VIVE
In the upcoming years, the U CAN-CER VIVE grant is set to foster groundbreaking studies, which are anticipated to expand significantly by 2025. Currently, Karmanos has ongoing studies tailored for patients grappling with conditions like metastatic adenocarcinoma of the pancreas. These initiatives align with Karmanos’ mission of improving cancer treatments while placing patients’ needs at the forefront of care.
Community and Collaboration in Fighting Cancer
Kelley LaFontaine, co-founder of U CAN-CER VIVE, reflects on the foundation’s deep-rooted motivation to support cancer research. This latest donation symbolizes more than just financial support; it's a testament to their faith in the researchers and the enduring strength of cancer patients. The collaboration between U CAN-CER VIVE and Karmanos exemplifies what can be achieved when communities unite to combat cancer.
Expanding Treatment Options for Patients
The TheraBionic P1 device works by emitting precisely calibrated radiofrequency electromagnetic fields, which are delivered directly to patients. This treatment modality allows patients to receive therapies comfortably at home, fostering better adherence and overall ease of use. These advancements set Karmanos apart as a leader in clinical trials, integrating personalized care through innovative technologies tailored to individual patient needs.
The Message of Hope
U CAN-CER VIVE focuses on creating sustainable change in cancer treatment paradigms. The efforts not only support clinical trials but also spread hope and awareness in the community, emphasizing that together, crucial strides can be made toward a future where fewer lives are lost to cancer.
Frequently Asked Questions
1. What is the purpose of U CAN-CER VIVE's donation?
The donation aims to fund research and clinical trials focused on innovative treatments using radiofrequency electromagnetic fields to combat various cancers.
2. Who are the founders of U CAN-CER VIVE?
U CAN-CER VIVE was co-founded by Ryan and Kelley LaFontaine.
3. What is the TheraBionic P1 device used for?
The TheraBionic P1 device is used to treat cancer by employing radiofrequency electromagnetic fields, specifically targeting liver cancer initially.
4. How has the TheraBionic P1 device been received by patients?
Patients have reported benefits such as tumor shrinkage and increased survival rates without experiencing severe side effects common with traditional treatments.
5. When are the new clinical trials expected to open?
The new clinical trials supported by the U CAN-CER VIVE grant are expected to begin opening in 2025.
